- $1.34bn
- $1.14bn
- $201.52m
- 86
- 15
- 81
- 63
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 61.3 | 98.7 | 126 | 158 | 202 |
Cost of Revenue | |||||
Gross Profit | 41.1 | 63.8 | 76.2 | 105 | 141 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 63.1 | 92.2 | 192 | 208 | 216 |
Operating Profit | -1.81 | 6.52 | -65.9 | -49.9 | -14.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.69 | 3.46 | -70 | -56.4 | -10.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.58 | -0.825 | -60.5 | -52.4 | -13.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -4.59 | -0.914 | -60.5 | -52.4 | -13.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.59 | -0.914 | -60.5 | -52.4 | -13.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.025 | -0.005 | -0.333 | -0.275 | -0.073 |
Dividends per Share |